Loading clinical trials...
Loading clinical trials...
A Phase II Study to Evaluate Safety, Tolerability and Efficacy, of CS0159 in Patients Subjects With Primary Sclerosing Cholangitis, Multicenter, Randomized, 12-week Double-blind, Placebo-controlled, and 40-week Open Study
Conditions
Interventions
CS0159
Locations
11
China
The First Affiliated Hospital of USTC Anhui Provincial Hospital
Hefei, Anhui, China
Beijing Friendship Hospital, Captail Medcial University
Beijing, Beijing Municipality, China
Beijing YouAn Hostital, Captial Medical University
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Wuhan Union Hospital of China
Wuhan, Hubei, China
The Seconed Xiangya Hospital of Central South University
Changsha, Hunan, China
Start Date
August 7, 2023
Primary Completion Date
November 14, 2025
Completion Date
May 1, 2026
Last Updated
March 13, 2026
NCT04753996
NCT05750498
NCT05295680
NCT02137668
NCT05740358
NCT04133792
Lead Sponsor
Cascade Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions